Posted by Michael Wonder on 15 Mar 2022
Drug industry says EMA’s PRIME scheme useful but could be improved
14 March 2022 - Eligibility criteria for admission to the EMA's priority medicines (PRIME) scheme are too strict to facilitate innovation in Europe according to the EFPIA.
The drug industry group made the comments to Regulatory Focus in response to the publication of a report on the first five years of the PRIME scheme.
